tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Mar 21;10(4)
fad154.
doi: 10.1093/ofid/ofad154. eCollection 2023 Apr.
Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
Aaron F Carlin[SUP] 1 [/SUP], Alex E Clark[SUP] 1 [/SUP], Aaron F Garretson[SUP] 1 [/SUP], William Bray[SUP] 1 [/SUP], Magali Porrachia[SUP] 1 [/SUP], AsherLev T Santos[SUP] 2 [/SUP], Tariq M Rana[SUP] 1 [/SUP], Antoine Chaillon[SUP] 1 [/SUP], Davey M Smith[SUP] 1 3 [/SUP]
Affiliations
Abstract
The factors contributing to the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.4 and BA.5 subvariants in populations that experienced recent surges of BA.2 and BA.2.12.1 infections are not understood. Neutralizing antibodies (NAbs) are likely to protect against severe disease if present in sufficient quantity. We found that after BA.2 or BA.2.12.1 infection, NAb responses were largely cross-neutralizing but were much less effective against BA.5. In addition, individuals who were infected and treated early with nirmatrelvir/ritonavir (Paxlovid) had lower NAb levels than untreated individuals.
Keywords: COVID-19; Omicron; neutralizing antibodies; nirmatrelvir/ritonavir; reinfection.
. 2023 Mar 21;10(4)
fad154.doi: 10.1093/ofid/ofad154. eCollection 2023 Apr.
Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
Aaron F Carlin[SUP] 1 [/SUP], Alex E Clark[SUP] 1 [/SUP], Aaron F Garretson[SUP] 1 [/SUP], William Bray[SUP] 1 [/SUP], Magali Porrachia[SUP] 1 [/SUP], AsherLev T Santos[SUP] 2 [/SUP], Tariq M Rana[SUP] 1 [/SUP], Antoine Chaillon[SUP] 1 [/SUP], Davey M Smith[SUP] 1 3 [/SUP]
Affiliations
- PMID: 37096144
- PMCID: PMC10122487
- DOI: 10.1093/ofid/ofad154
Abstract
The factors contributing to the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.4 and BA.5 subvariants in populations that experienced recent surges of BA.2 and BA.2.12.1 infections are not understood. Neutralizing antibodies (NAbs) are likely to protect against severe disease if present in sufficient quantity. We found that after BA.2 or BA.2.12.1 infection, NAb responses were largely cross-neutralizing but were much less effective against BA.5. In addition, individuals who were infected and treated early with nirmatrelvir/ritonavir (Paxlovid) had lower NAb levels than untreated individuals.
Keywords: COVID-19; Omicron; neutralizing antibodies; nirmatrelvir/ritonavir; reinfection.